TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"

Trial Profile

TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms BRAVERY TR
  • Most Recent Events

    • 02 May 2018 Status changed from not yet recruiting to recruiting.
    • 27 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top